Epigenomics: Tamoxifen treatment study results inconclusive

By Jennifer Chiou

New York, Oct. 31 - Epigenomics AG announced inconclusive results from a blinded study for its Tamoxifen treatment-response test developed to predict the probability of disease recurrence in breast cancer patients.

The company said the candidate markers could not be independently validated for technical reasons.

The collected data show irregularities with sample quality and input DNA concentrations, which led to an unusually high rate of sample exclusions, Epigenomics said.

Epigenomics and partner Roche Diagnostics are conducting data analysis and additional experiments.

Based in Berlin, Epigenomics is a molecular diagnostics company with a focus on cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.